Paul Hockings (Senior Director MR Imaging @ Antaros Medical and Adjunct Professor @ Chalmers University of Technology) will be presenting more interesting data this week at the 60th ERA Annual Congress.
This data comes from a long-standing collaboration between Antaros Medical, Sahlgrenska University Hospital, and AstraZeneca looking at non-invasive MRI biomarkers for use throughout drug development in diabetic kidney disease (DKD).
Previous results from this collaboration have shown that non-contrast multiparametric Magnetic Resonance Imaging (mpMRI) enables functional and structural assessment of DKD and that imaging endpoints can provide relevant information for predicting disease progression. This included a wide range of MRI biomarkers associated with kidney hemodynamics, oxygenation, and macro/microstructure that were assessed at baseline and at follow-up after 2 years. The findings suggest that certain imaging biomarkers may be predictors of disease progression, and that MRI could serve as a non-invasive tool for evaluating and predicting kidney disease progression.
The presented work is an expansion of this that evaluated the performance of additional MRI biomarkers and other lab biomarkers for predicting DKD progression. This allowed for comparisons to be made regarding the predictive value of MRI and other key lab biomarkers.
The European Renal Association (ERA) Annual Congress is the largest nephrology congress in Europe. This year it will take place from June 15-18 in Milan, Italy and virtually.
Abstract title: Multiparametric Magnetic Resonance Imaging biomarkers outperform lab biomarkers for predicting progression of diabetic kidney disease
Abstract number:
Authors: Hockings P, Makvandi K, Hulthe J, Baid-Agrawal S
Focused Oral in Chronic Kidney Disease session, June 17 at 8:30-9:45 CEST
Find the entire Scientific Programme here.